Literature DB >> 30561509

Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.

Marina R von Essen1, Cecilie Ammitzbøll1, Rikke H Hansen1, Eva R S Petersen1, Oskar McWilliam1, Hanne V Marquart2, Peter Damm3, Finn Sellebjerg1.   

Abstract

With the discovery that the highly effective anti-CD20 antibody therapies developed to deplete CD20+ B cells deplete CD20+ T cells equally well, a great interest in the biological properties of CD20+ T cells has emerged. In this study we show that CD20+ T cells have a proinflammatory Th1/Tc1 phenotype with a high proliferative capacity to CNS antigens. We also found that the percentage of CD20+ T cells is increased in the blood of patients with multiple sclerosis and are enriched in the CSF of the patients. Furthermore, we found a positive correlation between CD20+ T cells in the CSF and multiple sclerosis disease severity and see that regulation of CD20+ T cells likely contributes to the positive treatment effect of the multiple sclerosis treatment alemtuzumab. These data represent an important contribution to the understanding of the nature of CD20+ T cells and strongly suggests a role of CD20+ T cells in the pathogenesis of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30561509     DOI: 10.1093/brain/awy301

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  16 in total

Review 1.  Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.

Authors:  Finn Sellebjerg; Morten Blinkenberg; Per Soelberg Sorensen
Journal:  CNS Drugs       Date:  2020-03       Impact factor: 5.749

2.  Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis.

Authors:  Marina Rode von Essen; Rikke Holm Hansen; Camilla Højgaard; Cecilie Ammitzbøll; Heinz Wiendl; Finn Sellebjerg
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-06-07

Review 3.  Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal Models.

Authors:  Taryn E Mockus; Ashley Munie; Jeffrey R Atkinson; Benjamin M Segal
Journal:  J Immunol       Date:  2021-01-01       Impact factor: 5.422

4.  Integrated analysis of differentially expressed genes and a ceRNA network to identify hub lncRNAs and potential drugs for multiple sclerosis.

Authors:  Tianfeng Wang; Si Xu; Li Liu; Shuang Li; Huixue Zhang; Xiaoyu Lu; Xiaotong Kong; Danyang Li; Jianjian Wang; Lihua Wang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

Review 5.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

6.  Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx.

Authors:  Marcus A Carden; Manila Gaddh; Abhinav Hoskote; Michael Brown; Virginia Merrill; Sean R Stowell; Shanmuganathan Chandrakasan; Ana Antun; Ragini Kudchadkar; Sarah Kotanchiyev; David L Jaye; Imre Bodó
Journal:  Blood Adv       Date:  2020-02-11

7.  Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.

Authors:  Diethilde Theil; Paul Smith; Catherine Huck; Yoann Gilbart; Algirdas Kakarieka; David Leppert; Celine Rauld; Cindy Schmid; Reto Baumgartner; Nathalie Stuber; Francisco Cordoba; Valerie Dubost; Katy Darribat; Magali Jivkov; Wilfried Frieauff; Rainer Kneuer; Markus Stoeckli; Stefan Reinker; Keith Mansfield; José M Carballido; Philippe Couttet; Gisbert Weckbecker
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

8.  Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis.

Authors:  Joseph J Sabatino; Michael R Wilson; Peter A Calabresi; Stephen L Hauser; Jonathan P Schneck; Scott S Zamvil
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-20       Impact factor: 11.205

Review 9.  Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis.

Authors:  Charles A Roach; Anne H Cross
Journal:  Front Neurol       Date:  2021-01-22       Impact factor: 4.003

10.  B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis.

Authors:  Nitzan Nissimov; Zivar Hajiyeva; Sebastian Torke; Katja Grondey; Wolfgang Brück; Silke Häusser-Kinzel; Martin S Weber
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.